Metabolism, excretion, and mass balance of the hiv-1 integrase inhibitor dolutegravir in humans

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3536-3546

  Castellino, Stephen ^a   Moss, Lee ^a   Wagner, David ^a   Borland, Julie ^a   Song, Ivy ^a   Chen, Shuguang ^a   Lou, Yu ^a   Min, Sherene S ^a   Goljer, Igor ^a   Culp, Amanda ^a   Piscitelli, Stephen C ^a   Savina, Paul M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DOLUTEGRAVIR; DOLUTEGRAVIR C14; ETHER; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE; INTEGRASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DEFLUORINATION; DIARRHEA; DRUG ABSORPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERANCE; ENZYME METABOLISM; FECES; HUMAN; HUMAN EXPERIMENT; MALE; METABOLITE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; URINE;

ADULT; CYTOCHROME P-450 CYP3A; DRUG TOLERANCE; FECES; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HALOGENATION; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 84880268976     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00292-13     Document Type: Article

References (22)

1. Engelman A, Craigie R. 1992. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J. Virol. 66:6361-6369.
2. Semenova EA, Johnson AA, Marchand C, Davis DA, Yarchoan R, Pommier Y. 2006. Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by alpha-hydroxytropolones. Mol. Pharmacol. 69:1454-1460.
3. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236.
4. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. 2010. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. U. S. A. 107: 20057-20062.
5. Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. 2011. Structural and functional analyses of the secondgeneration integrase strand transfer inhibitor dolutegravir (S/ GSK1349572). Mol. Pharmacol. 80:565-572.
6. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. 2011. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55:813-821.
7. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL, III, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55:4552-4559.
8. Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J. 2011. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 25: 1737-1745.
9. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S. 2012. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviralnaïve adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect. Dis. 12:111-118.
10. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fugiwara T, Huang J, Min S, Vavro C, Yeo J. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J. Infect. Dis. doi:10.1093/infdis/jis750.
11. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC. 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54:254-258.
12. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD Polli JW. 2013. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab. Dispos. 41:353-361.
13. Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research. 2005. Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. U. S. Department of Health and Human Services, Rockville, M. D.
14. Chen S, Min SS, Peppercorn A, Borland J, Lou Y, Song I, Fujiwara T, Piscitelli SC. 2012. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Pharmacotherapy 32:333-339.
15. Loevinger RL, Budinger TF, Watson EE. 1999. MIRD primer for absorbed dose calculations, revised ed. Society of Nuclear Medicine, New York, N. Y.
16. Yang X, Gandhi YA, Duignan DB, Morris ME. 2009. Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J. 11:511-525.
17. Rao SSC, Camilleri M, Hasler WL, Maurer AH, Parkman HP, Saad R, Scott MS, Simren M, Soffer E, Szarka L. 2011. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol. Motil. 23:8-23.
18. Song I, Borland J, Chen S, Patel P, Wajima T, Peppercorn A, Piscitelli S. 2012. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob. Agents Chemother. 56:1627-1629.
19. Dear GJ, Ismail IM, Mutch PJ, Plumb RS, Davies LH, Sweatman BC. 2000. Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in rabbit, mouse and human: identification of fluorine NIH shift metabolites using NMR and tandem MS. Xenobiotica 30:407-426.
20. Yergey JA, Trimble LA, Silva J, Chauret N, Li C, Therien M, Grimm E, Nicoll-Griffith DA. 2001. In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization. Drug Metab. Dispos. 29:638-644.
21. Samuel K, Yin W, Stearns RA, Tang YS, Chaudhary AG, Jewell JP, Lanza T, Jr, Lin LS, Hagmann WK, Evans DC, Kumar S. 2003. Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J. Mass Spectrom. 38:211-221.
22. Smith DA, Obach RS. 2009. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22:267-279.